Every Cure
Every Cure is a Philadelphia-based nonprofit using an AI-powered computational pharmacophenomics platform to systematically identify and clinically advance repurposed uses of approved drugs, serving patients with the ~14,000 recognized diseases that lack FDA-approved treatments.
- Company typePrivate
- Founded2022
- HeadquartersNew York, United States
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What Every Cure does
Every Cure is a 501(c)(3) nonprofit organization founded in September 2022 and headquartered in Philadelphia, Pennsylvania, with the mission of systematically identifying and advancing drug repurposing opportunities to treat diseases lacking approved or adequate therapies. The organization was co-founded by Dr. David Fajgenbaum, a physician-scientist who saved his own life by repurposing sirolimus for idiopathic multicentric Castleman disease and has since advanced 14 repurposed treatments across Castleman disease, angiosarcoma, DADA2 syndrome, and other rare conditions; Dr. Grant Mitchell, formerly of McKinsey/QuantumBlack; and Tracey Sikora, who brings a decade of rare disease drug repurposing experience. Every Cure targets a defined unmet need: more than 300 million people globally have diseases without FDA-approved treatment, and only ~4,000 of ~18,000 recognized diseases have any approved therapy at all, leaving commercial drug developers with little financial incentive to pursue new uses for off-patent molecules.
The organization's core offering is an AI-powered computational pharmacophenomics platform (also referred to as MATRIX) that combines three approaches: a knowledge graph integrating over 100 biomedical datasets covering drug mechanisms, gene interactions, and disease pathways; LLM-based agentic workflows that emulate clinical reasoning chains; and real-world evidence models trained on prescription and medical record data. The platform ranks potential drug-disease matches and currently evaluates 66 million possible pairings across 3,000 approved drugs and 22,000 diseases within days. Every Cure complements this platform with an active pipeline of 10 drug repurposing programs organized into Frontier Explorers (laboratory studies), Clinical Gems (clinical studies), and Unsung Heroes (patient access programs), plus the ROADMAP Project published in JAMA Network Open, which provides a framework for rare disease organizations to pursue their own repurposing efforts.
Every Cure generates no commercial revenue; instead, it is funded by philanthropic donations, foundation grants, and government contracts. Cumulative fundraising reached approximately $110 million by October 2024, anchored by a $48.3 million three-year contract from ARPA-H (with up to $76 million announced for Phase 2) and a five-year $60 million commitment from TED's Audacious Project, alongside foundational grants from the Chan Zuckerberg Initiative, Flagship Pioneering, Lyda Hill Philanthropies, Elevate Prize Foundation, and Arnold Ventures. Distribution of Every Cure's outputs occurs through academic publications (NEJM, Lancet, Blood), inclusion in clinical guidelines (UpToDate, NCCN), partnerships with patient organizations and CROs (Worldwide Clinical Trials), medical conference dissemination, and open-source data releases. The organization does not sell products or services; its "customers" are patients with rare and undertreated diseases, whose outcomes (documented remissions, hospice-to-recovery case studies) function as the organization's impact metrics.
Every Cure firmographics
Firmographics- Name
- Every Cure
- Legal name
- Every Cure, Inc.
- Website
- https://everycure.org
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Every Cure is a Philadelphia-based nonprofit using an AI-powered computational pharmacophenomics platform to systematically identify and clinically advance repurposed uses of approved drugs, serving patients with the ~14,000 recognized diseases that lack FDA-approved treatments.
- Ownership category
- akta.pro rank
Every Cure industry classification
Industry- Product category
- AI Drug Repurposing Platform
- SIC
- Services-Prepackaged Software (7372), Services-Health Services (8000)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE), Healthcare Outcomes & Real-World Evidence (RWE) Analytics (BPAHALAN)
Keywords
Where Every Cure is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Every Cure business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Philanthropic Donations: Every Cure is a nonprofit organization that relies on donations from individuals, foundations, and corporate giving programs. Donations can be made through their website and are tax-deductible under Section 501(c)(3) of the Internal Revenue Code (EIN: 92-0240717).
- Government Grants: The organization receives significant government funding including a $48.3 million contract from ARPA-H and is pursuing additional federal funding to support its AI platform development and clinical research programs.
- Corporate and Foundation Partnerships: Funding from strategic philanthropists including TED's Audacious Project ($60M commitment over 5 years), Chan Zuckerberg Initiative, Flagship Pioneering, Lyda Hill Philanthropies, Elevate Prize Foundation, and others.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels7 records
Every Cure product offering
Product offeringCore offering
Every Cure operates an AI-powered computational pharmacophenomics platform that systematically scans across 3,000 approved drugs and 22,000 recognized diseases to identify and rank the highest-potential drug repurposing opportunities, generating efficacy scores for 66 million drug-disease matches within days. The organization takes end-to-end responsibility from AI-based identification through laboratory validation, clinical studies, and patient access programs for diseases lacking approved or affordable treatments.
Product overview
Every Cure operates as a nonprofit biotech organization that offers an integrated AI-powered drug repurposing ecosystem. The core offering is the Computational Pharmacophenomics AI Platform (also called MATRIX), which systematically scans across 3,000 approved drugs and 22,000 recognized diseases to identify and prioritize drug repurposing opportunities. This platform is complemented by the ROADMAP Project, which provides guidance tools for rare disease organizations, and the company's Pipeline/Portfolio of active drug repurposing programs. The organization takes end-to-end responsibility from AI identification through clinical validation to patient access.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- First patient treated with AI-identified drug (adalimumab for Castleman disease) achieved remission after being headed to hospice
- +3 more outcomes
Companies that use Every Cure
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
Every Cure technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability6 records
Feature4 records
Every Cure partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- Corewell Health and Michigan State UniversitycoreCollaboration on Bachmann-Bupp Syndrome (BABS) and repurposing of DFMO/eflornithine to ensure no patient goes undiagnosed and to advance treatment access.
- ConscienceminorPartnership to advance drug repurposing initiatives, combining resources to expand reach and impact in identifying treatments for underserved diseases.
- Google CloudcoreExpanded collaboration leveraging Google Cloud's infrastructure and AI technologies including Gemini 2.0 to accelerate drug repurposing discoveries and improve patient outcomes.
- BioPhycoreDeployed BioPhy's artificial intelligence platform to accelerate drug repurposing efforts, enhance computational drug development, and enable clinical trial simulation capabilities.
- Atropos HealthcoreLeveraging Atropos Health's GENEVA OS and Evidence Network to enable real-world data confirmation of drug repurposing opportunities and trial emulation capabilities to speed clinical development.
- Worldwide Clinical TrialscorePartnership with leading global full-service contract research organization (CRO) to accelerate discovery of treatments for rare disease patients through clinical trial support.
- Castleman Disease Collaborative Network (CDCN)coreCo-founded by Dr. Fajgenbaum in 2012, CDCN is a key partner in advancing treatments for Castleman disease and related conditions through patient-driven initiatives.
- University of Pennsylvania - Center for Cytokine Storm Treatment & LaboratorycoreAcademic partner institution led by Dr. Fajgenbaum where foundational drug repurposing research was conducted, including the sirolimus discovery for Castleman disease.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
Every Cure competitors and assessment
Company assessmentBroad incumbents
- Owkin: AI-for-drug-discovery and clinical-research platform using real-world patient data and federated learning to accelerate therapeutics development; overlaps with Every Cure in using real-world evidence and AI for drug-disease matching and trial design.
Emerging players
- Lantern Pharma: AI-driven oncology platform (RADR) that identifies responders and repurposes compounds for cancer indications; an emerging peer applying AI to drug-repurposing selection and trial design in a focused therapeutic area.
Direct peers
- Recursion Pharmaceuticals: AI-native drug discovery company combining high-throughput biology with machine learning to identify novel therapeutics; comparable to Every Cure as a data-and-AI-driven approach to expanding the druggable space, though focused on de novo discovery rather than repurposing.
- BPGbio: AI-driven biology and drug-repurposing company with an oncology-led pipeline of repurposed and novel compounds; comparable in pairing a Bayesian/AI discovery platform with a focus on repurposing for diseases with high unmet need.
- Healx: AI-driven drug repurposing company focused specifically on rare diseases, combining knowledge graphs with patient and disease data to identify treatments; the closest peer to Every Cure in combining AI repurposing with a rare-disease mission.
- BenevolentAI: Knowledge-graph-based AI platform for drug discovery and repurposing, including systematic identification of new indications for existing drugs; among the closest direct competitors in AI-enabled drug repurposing.
- Exscientia: AI-driven precision medicine company using patient-derived data and active-learning platforms to accelerate small-molecule drug design; comparable to Every Cure in using AI to systematically map drug–disease relationships and prioritize candidates.
- Insilico Medicine: Applies generative AI and deep learning to identify novel drug targets and molecules across multiple therapeutic areas; a directly comparable AI-driven drug-discovery platform with similar knowledge-graph and predictive-modeling methodologies.
- Atomwise: Uses AI (structure-based small-molecule design and screening) to discover and advance novel and repurposed therapeutics, partnering with pharma on pipeline programs; comparable in applying AI to systematically evaluate large drug–disease spaces.
Others
- Castleman Disease Collaborative Network (CDCN): Patient-organization partner co-founded by Dr. Fajgenbaum in 2012 and a key ecosystem collaborator for Every Cure; not a competitor but the closest peer-organization in disease-advocacy-driven drug repurposing for rare conditions.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Every Cure social profiles
Digital presenceEvery Cure financial estimates
Financial estimateRevenue estimate
Valuation estimate
Every Cure leadership team
Management profileNumber of profiles
Profiles12 records
Every Cure funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Every Cure M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Every Cure
What does Every Cure do?
Every Cure operates an AI-powered computational pharmacophenomics platform that systematically scans across 3,000 approved drugs and 22,000 recognized diseases to identify and rank the highest-potential drug repurposing opportunities, generating efficacy scores for 66 million drug-disease matches within days. The organization takes end-to-end responsibility from AI-based identification through laboratory validation, clinical studies, and patient access programs for diseases lacking approved or affordable treatments.
Is Every Cure a public or private company?
Every Cure is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Every Cure founded?
Every Cure was founded in 2022. It employs 51 to 100 people.
Where is Every Cure based?
Every Cure is headquartered in New York, United States, in the North America region.
How does Every Cure make money?
Three revenue lines are on record. Philanthropic Donations are the primary driver. The others are government Grants and corporate and Foundation Partnerships.
Who are Every Cure's main competitors?
Owkin is listed as a broad incumbent. Lantern Pharma is listed as an emerging player. Direct peers are Recursion Pharmaceuticals, BPGbio, Healx, BenevolentAI, Exscientia, Insilico Medicine and Atomwise. Castleman Disease Collaborative Network (CDCN) is listed as an others.
Does Every Cure have an API?
No public API is recorded for Every Cure.
What industry is Every Cure in?
Every Cure's product category is AI Drug Repurposing Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its SIC code is 7372.